补肾活血法对绝经后妇女骨质疏松骨代谢的影响
|
摘要
目的：
对患者西医诊断及中医辩证,针对绝经后骨质疏松患者进行干预,研究分析补肾活血法对骨质疏松患者骨代谢指标的影响,分析补肾活血法干预骨代谢生化指标的变化。揭示中医药对绝经后妇女骨质疏松症可能作用机制,并为中医药治疗绝经后妇女骨质疏松提供依据和支持。并为临床治疗提供新选择。
方法：
按照纳入标准和排除标准标准选取广东省中医院大学城医院骨科2011年6月至2012年2月份住院患者59例,随机分为试验组30例,对照组29例。试验组给予钙尔奇D600mg,qd；骨化三醇0.25ug,bid；骨松安胶囊4片,tid。,对照组单纯给予钙尔奇D600mg,qd；骨化三醇0.25ug,bid；福善美1片70mg,qw,观察两组病例治疗前后ALP、N-MID、PINP、CTX的变化,将相关参数录入数据库。建立SPSS13.0数据库系统,运用统计学软件进行分析,得出结论。
结果：
1.试验组和对照组治疗前后ALP、N-MID、PINP、CTX各指标有显著性差异(P<0.05),差异有统计学意义。
2.试验组和对照组的治疗前ALP、N-MID、PINP、CTX各指标比较无显著性差异(P>0.05),差异无统计学意义。
3.试验组和对照组治疗后N-MID、PINP、CTX指标比较有显著性差异(P<0.05),差异有统计学意义；ALP无显著性差异(P>0.05),差异无统计学意义。
结论：
补肾活血法(骨松安胶囊)治疗绝经后妇女骨质疏松方面可明显抑制破骨作用和促进骨合成,从而改善患者骨质疏松。
Objectives
To objective the kidney and activating blood on bone metabolism in patiets with postmenopausal osteoporosis.
Methods
59postmenopausal women with osteoporosis were enrolled, who were randomly divided into2groups according to30:29ratio.the experimental group was given Calcitrio10.25ug、Bone Song-capsule4pills and Catrate D600, the control group was given Calcitrio10.25ug、alendronate sodiumlpill and Caltrate D600. All of the patients were received singe blind treatment for2months.
Results
At the2th months,the change of bone biochemical markers was significance, resoectively in experimental group and control group.2months later, the PINP in experimental group was decreased40%(P<0.05),CTX in experimental group was decreased52%(p<0.05), N-MID in experimental group was decreased54%(p<0.05), ALP in experimental group was decreased7%(p<0.05). There was no new spine bone fracture in lateral projection of lumbar vertebrate and thoracic vertebrae in two group, While there was no bone fracture in other site. No serious adverse effects were observed during the trial.
Conclusion
Kidney and Activating Blood inhibit bone resorption and increase bone formation. It has less adverse effects. It is a desirable prophylactic and treatment drug of osteoporosis in post menopausal women
对患者西医诊断及中医辩证,针对绝经后骨质疏松患者进行干预,研究分析补肾活血法对骨质疏松患者骨代谢指标的影响,分析补肾活血法干预骨代谢生化指标的变化。揭示中医药对绝经后妇女骨质疏松症可能作用机制,并为中医药治疗绝经后妇女骨质疏松提供依据和支持。并为临床治疗提供新选择。
方法：
按照纳入标准和排除标准标准选取广东省中医院大学城医院骨科2011年6月至2012年2月份住院患者59例,随机分为试验组30例,对照组29例。试验组给予钙尔奇D600mg,qd；骨化三醇0.25ug,bid；骨松安胶囊4片,tid。,对照组单纯给予钙尔奇D600mg,qd；骨化三醇0.25ug,bid；福善美1片70mg,qw,观察两组病例治疗前后ALP、N-MID、PINP、CTX的变化,将相关参数录入数据库。建立SPSS13.0数据库系统,运用统计学软件进行分析,得出结论。
结果：
1.试验组和对照组治疗前后ALP、N-MID、PINP、CTX各指标有显著性差异(P<0.05),差异有统计学意义。
2.试验组和对照组的治疗前ALP、N-MID、PINP、CTX各指标比较无显著性差异(P>0.05),差异无统计学意义。
3.试验组和对照组治疗后N-MID、PINP、CTX指标比较有显著性差异(P<0.05),差异有统计学意义；ALP无显著性差异(P>0.05),差异无统计学意义。
结论：
补肾活血法(骨松安胶囊)治疗绝经后妇女骨质疏松方面可明显抑制破骨作用和促进骨合成,从而改善患者骨质疏松。
Objectives
To objective the kidney and activating blood on bone metabolism in patiets with postmenopausal osteoporosis.
Methods
59postmenopausal women with osteoporosis were enrolled, who were randomly divided into2groups according to30:29ratio.the experimental group was given Calcitrio10.25ug、Bone Song-capsule4pills and Catrate D600, the control group was given Calcitrio10.25ug、alendronate sodiumlpill and Caltrate D600. All of the patients were received singe blind treatment for2months.
Results
At the2th months,the change of bone biochemical markers was significance, resoectively in experimental group and control group.2months later, the PINP in experimental group was decreased40%(P<0.05),CTX in experimental group was decreased52%(p<0.05), N-MID in experimental group was decreased54%(p<0.05), ALP in experimental group was decreased7%(p<0.05). There was no new spine bone fracture in lateral projection of lumbar vertebrate and thoracic vertebrae in two group, While there was no bone fracture in other site. No serious adverse effects were observed during the trial.
Conclusion
Kidney and Activating Blood inhibit bone resorption and increase bone formation. It has less adverse effects. It is a desirable prophylactic and treatment drug of osteoporosis in post menopausal women
引文
[1]Consensus Development Panel on Osteoporosis Prevention Diagnosis and Therapy. Osteoporosis prevention, diagnosis, and therapy. Journal of the American Medical Association,2001,285(18):2323—2324
[2]Nguye TV.Association between breast cancer and bone mineral density:the duboosteopporosise,2008,28(23):2386—2388
[3]彭宣灏,王萍,王爱民.中药防治骨质疏松研究现状综述[J].中国当代医学,2005,4(17)：53—58
[4]吴淑金,徐栋梁,林万莲.中医药补肾治疗骨质疏松症的研究概况[J].国际医药卫生导报,2004,10(10)：187—188
[5]赵玉堂,刘凯军,李金花,等.骨矿含量与肾虚、肾主骨关系的研究[J].中国骨质疏松杂志,1996,2(3)：19—22
[6]胡年宏,刘庆思.补肾健脾活血法防治骨质疏松症的研究概况[J].中医正骨,2004, 16(5)：53—54
[7]王攀攀,张荣华,朱晓峰,等.肝与骨质疏松症关系探析[J].时珍国医国药,2009,20(10)；2632-2633
[8]郭秋菊,眭承志.血瘀与老年性骨质疏松症关系的研究进展[J].河北中医,2009,31(2)：306—307
[9]王新,方楚权,林远芳,等.苠藿丹健骨方治疗绝经后骨质疏松症50例疗效观察[J].新中医,2006,38(5)：22—23
[10]林一峰,邵敏,刘庆思,等.中药骨康治疗绝经后骨质疏松症患者2年临床研究[J].中国骨质疏松杂志,2009,15(4)：288—291
[11]张荣华,陈可冀,陆大祥,等.益骨胶囊治疗绝经后骨质疏松症的临床研究[J].中国中西医结合杂志,2004,24(8)：680—684
[12]许旺,陈玉辰,张景凤,等.益肾养肝合剂治疗肝肾不足型绝经后骨质疏松症临床观察[J].中草药,2005,36(6)：898—899
[13]光爱珍.六昧地黄丸加虎潜丸治疗绝经后骨质疏松症[J].中国民间疗法,2010, 18(4)：41
[14]阿依加曼·阿不拉,艾合买提·托合尼亚孜.绝经后骨质疏松症治疗133例分析[J].新疆医科大学学报,2006,29(6)：548—549
[15]张银萍,崔英华,康红钰,等.实骨饮对绝经后骨质疏松症患者骨形成、破坏指标的影响及疗效观察[J].新中医,2007, 39(1)：30-31
[16]章林.补肾括血汤治疗绝经后骨质疏松症30例临床观察[J].湖南中医药导报,2004,10(6)：52—53,87
[17]李煜明.补肾活血剂治疗绝经后骨质疏松症60例[J].南京中医药大学学报,2005, 21(1)：56—57
[18]莫传伟.绝经后骨质疏松症中医证候特征及生存质量研究[D].广州中医药大学,2005：1—3
[19]李青南.淫羊藿提取液对去睾丸大鼠代谢的影响[J].中草药,1993, 24(12)：637
[20]熊鹏程,甘学文.补肾健脾活血方对大鼠成骨细胞增殖的影响[J].湖北中医杂志,2006,28(1)：9-10
[21]漆海如,黄永明.中医药对成骨细胞作用的研究进展[J].中医正骨,2006, 18(1)：66—67
[22]臧洪敏,陈君长,刘亦恒,等.补肾活血方对成骨细胞增殖等生物学特性影响的实验研究[J].药材,2005,28(9)：803—805
[23]汤耿民,沈霖,涂意辉,等.补肾活血方对成骨细胞生长因子TGF-β 1mRNA表达的影响[J].中国中医骨伤科杂志,1999, 7(5)：5—7
[24]肖德建.实用骨质疏松学[M].北京：北京科学出版社,2004.276.
[25]崔寿昌.骨质疏松症的预防[J].中国健康教育,2006,22(7)：528-530
[26]郭华平,等.绝经后骨质疏松症发病相关危险因素分析及预防措施探讨[J].中国康复医学杂志,2011,26(5)
[27]周亮,江钟立,林枫,等.青年人和老年人词汇联想反应的研究[J].中国康复医学杂志,2008,23(4)：297—300
[28]徐洁,赵东宝,刘文斌.上海市社区中老年人骨密度相关影响因素分析[J].中国康复医学杂志,2010,25(1)：68—69
[29]郭华平等.绝经后骨质疏松症发病相关危险因素分析及预防措施探讨[J].中国康复医学杂志,2011年,26(5)
[30]Guadalupe-Grau A, Fuentes T, Guerra B, etal. Exercise and bone mass in adults[J]. Sports Medicine,2009,39(6):439—468
[31]de Matos O, Lopesda Silva DJ,Martinez de Oliveira J, et al. Effect of specific exercise training on bone mineral density in women with postmenopausal osteopenia or osteoporosis [J]. Gynecological Endocrinology,2009,25(9):616-620
[32]刘忠厚,主编.骨矿与临床[M].北京：中国科学技术出版社,2006：641
[33]M anolagas SC. Birth and death of bone cells:basic regulatory me chanisms and implications for the pathogenesis and treatment of osteoporosis[J]. Endocrine Reviews,2000,21(2):115-137
[34]M anolagas SC,Kousteni S. Perspective non-reproductive sites of action of reproductive hormones[J]. Endocrinology,2001,142 (6):2200-2204
[35]Kousteni. S, Chen JR, Belli do T, et a.1 Reversal of bone loss in mice by non-genotropic signaling of sex steroids[J].Science,2002,298(5594):843—846
[36]赵荣,陶静.原发性骨质疏松症的病因学研究进展[J].云南中医学院学报,2007,30(2)：67—70
[37]Kallio DM, Garant PR, Minkin CU ltrastructural effects of calciton in on osteoclasts in tissue culture[J]J U ltrastruct Research,1972,39(3).205—216
[38]高建军,周轶,顾淑珠,等.依降钙素对破骨细胞的作用观察[J].中国骨质疏松杂志,2002,8(3)248—252
[39]赵荣,陶静.原发性骨质疏松症的病因学研究进展[J].云南中医学院学报,2007, 30(2)：67—70
[40]邵洵.老年人骨质疏松临床症状及流行病因分析[J].中国健康月刊2010年第29卷第7期
[41]The National Osteoporosis Risk Assessment, NORA
[42]Wu XP, Liao EY, Huang G, et al.A comparison study of the reference curves of bone mineral density at different skeletal sites in native Chinese, Japanese, and American Caucasian women. Calcif Tissue Int,2003,73:122-132
[43]Koh LK, Sedrine WB, TorralbaTP, et al.Asimple tool to identify asianwomen at increased risk of osteoporosis. Osteoporos Int.,2001,12(8):699—705
[44]朱汉民.原发性骨质疏松症防治的进展和趋势.老年医学与保健,2003,9：67—68
[45]Sambrook P, Cooper C. Osteoporosis. Lancet,2006,17:201022018. of osteoporosis. Osteoporos Int.,2001,12(8):699—705
[46]朱继衍,杨蕊敏.老年人骨折与骨密度及骨代谢生化测定探讨.中国老年志,2002,22：190—191
[47]Hernandez MV.Guanabens N, Alvarez L, et al. Immunocytochemical evidence on the effects of glucocorticoids on type I collagen synthesis in human osteoblastic cells. Calcif Tissue Int,2004,74:284-293
[48]Li Y L,Li YY, An Y Q. The effect of monos odium glutamate on the growth and immue function in rat. Journal of Capital University of medical sciences,1997,18(3):210 —221
[49]G arcia2Perez MA, Moreno2Mercer J, Tarin JJ, et al. Similar efficacy of low and standard doses of transdermal estradiol in controlling boneturnover in postmenopausal women. G ynecol Endocrinol,2006,22(4):179—184
[50]Sornay RE, Munoz F, Garnero P, et al. Identification of osteopenic women at high risk of fracture. J Bone Miner Res,2005,20:1813—1819
[51]Wolfe-BM, Huff MW. Effects of continuous low-dosage hor-monal replacement therapy on lipoprotein metabolism in post-menopausal women. Metabolism,1995,44(3):410—417
[52]黄毅,王越.激素替代疗法治疗骨质疏松症的现状和展望[J].医药报,2000,19(2)：177-178
[53]黄德芳,高玉芬,朱明月,等Rallaoxifene对去卵巢大鼠子宫内膜的影响[J].中国骨质疏松杂志,2001,7(3)：241—243
[54]Ott SM. Clinical effects of bisphosphonates in involutional os-teoporosis[J]. JBone Miner Res,1993,8(S2):S597-606
[55]徐春生,叶仁青.氟化物在骨质疏松症治疗中的应用[J].国外医学内分泌学分册,1998,18(2)：78—81
[56]Startoris DJ, Editor. Osteoporosis-diagnosis and treatment [M]. New York:Marcel Dekker,1996,303
[57]Lindsay R. Fluoride and bone:quantity versus quality[J]. NEngl J Med,1990,322 (12):845-846
[58]Riis B, Thomsen AL. Does calcium supplementation prerentp ostmenopausal bone loss? [J]. N Engl J Med,1987,316(4):173-177
[59]Recker R, Kimmwl DB, Hinders, et al. Determinants of en-dogenous fecal calcium in healthy weren[J]. J Bone MinerRes,1994,9(Suppl 1):S154
[60]Brennan MJ. In vitro dissolution of calcium carbonate preparations[J]. Calcif Tissue Int,1991,49 (5):308—312
[61]徐淑云,等.临床药理学.北京人民卫生出版社,2004,7(3)：403-413.
[62]Baltas CS. Balanika AP, Raptou PD, et al. Clinical practice guidelines proposed by the Hellenic Foundation of Osteoporosis for the management of osteoporosis based on DXA results[J]. J Musculoskelet Neuronal Interact,2005,5(4):388-392.
[63]Arimandi BH, Ahekel L, Hollis BW, et al. Dietary soybeanproteinprevents bone loss in an ovariectomized rat model ofosteoporosis[J]. J Nutr,1996,42(6):161—167
[64]Arimandi BH, Birnbaum R, Goyal NV, et al. Bone-sparingeffect of soyprotein in ovarian-homone deficient rats is related to its is oflavonecontent[J]Am J clin Mctr,1998,68(Sup-pl):1364-1368
[65]Somekama Y,Chiguchi M,Zshibashi T, et al Soy intake relat-ed to menopausal symptoms, serum lipids and bone mineral density in postmenopausal Japanese woman[J]Obstet Gynecol,2001,97(1):109—115
[66]赵玉堂,刘凯军,李金花,等.骨矿含量与肾虚、肾主骨关系的研究[J].中国骨质疏松杂志,1996,2(3)：19—22
[67]黄永明,许少健,石宇雄,等.骨松安胶囊治疗绝经后骨质疏松症34例[J],陕西中医2006,27(8)：954-956
[68]姚新苗.益骨汤含药血清对成骨细胞增殖和ALP影响的实验研究[J].浙江中医药大学学报,2007,31(2)：1—2
[69]张拔山,曾龙宏,等.2型糖尿病患者骨代谢生化指标的临床意义[J].放射免疫学杂志,2004,17(4)：251—253
[70]李青南.淫羊藿提取液对去睾丸大鼠代谢的影响[J].中草药,1993, 24(12)：637
[71]安胜军.雌激素、雌激素受体、雌激素受体基因与骨质疏船[J].现代康复.2001,5(2)：7—8
[72]SUDA T, NAKAMURA I, JIMI E, et al. Regulation of osteoclast function[J]. J Bone Miner Res.1997,12:869-879
[73]Herrmann M, Seibol M. The alnlno and carboxyterminal corss-linked telopeptldes of collagen type Ⅰ. NTX-Ⅰ and CTX-Ⅰ:a comparative re-view[J]. Clinical Chimica Aeta, 2008,393:57-75
[74]甘洁民,缪应新,朱汉民.骨代谢生化标志物的分析与临床参考值的设立[J].老年医学与保健,2005,11：165—167
[75]Ross PD, Knowlton W. Rapid bone loss is associated with increased levels of biochemical markers [J]. J Bone Miner Res,1998,13:297—302
[76]Rotteveel J, Schoute E, Delemarre W, et al. Serum procollagen I carboxyterminal pmpepf ide(PICP) levels through puberty:relation to height velocity and serum hormone levels [J]. Acta Pediatrica,1997,86(2):143-147
[77]Jacques PB, Caroline A, Bassam AN, et al. Bone turnover markers in the management of postmenopausal osteoporosis[J]. Clin Biochem,2009,42(10—11): 929-942
[78]Dommguez CC, Sosa HM, Traba ML et al. Biochemical markers of bone formetion in the study of postmenopausal osteoporosis.Osteoporosis Int.1998,27 (2):147—151
[79]Gamero P. Delmas PD. Biochemical markers of turnover. Endocrinol Metab Clin North Am.1998,27(2):303-322
[80]Germero P.Delmas PD Osteoporosis Endoctmal Metab Clin North Am.1997,26(2):913-936
[81]Lursetto G, Bottega F. Nardi A et al. Decrease of bone formation in adult women with fragility fractures Matunatas,1997,28(1):59—67
[82]杨波,舒娜翎,崔党珍,等.健康中老年人768例血浆骨源性ALP测定结果分析[J],中国误诊学杂志,2005,15(5)：2909.
[2]Nguye TV.Association between breast cancer and bone mineral density:the duboosteopporosise,2008,28(23):2386—2388
[3]彭宣灏,王萍,王爱民.中药防治骨质疏松研究现状综述[J].中国当代医学,2005,4(17)：53—58
[4]吴淑金,徐栋梁,林万莲.中医药补肾治疗骨质疏松症的研究概况[J].国际医药卫生导报,2004,10(10)：187—188
[5]赵玉堂,刘凯军,李金花,等.骨矿含量与肾虚、肾主骨关系的研究[J].中国骨质疏松杂志,1996,2(3)：19—22
[6]胡年宏,刘庆思.补肾健脾活血法防治骨质疏松症的研究概况[J].中医正骨,2004, 16(5)：53—54
[7]王攀攀,张荣华,朱晓峰,等.肝与骨质疏松症关系探析[J].时珍国医国药,2009,20(10)；2632-2633
[8]郭秋菊,眭承志.血瘀与老年性骨质疏松症关系的研究进展[J].河北中医,2009,31(2)：306—307
[9]王新,方楚权,林远芳,等.苠藿丹健骨方治疗绝经后骨质疏松症50例疗效观察[J].新中医,2006,38(5)：22—23
[10]林一峰,邵敏,刘庆思,等.中药骨康治疗绝经后骨质疏松症患者2年临床研究[J].中国骨质疏松杂志,2009,15(4)：288—291
[11]张荣华,陈可冀,陆大祥,等.益骨胶囊治疗绝经后骨质疏松症的临床研究[J].中国中西医结合杂志,2004,24(8)：680—684
[12]许旺,陈玉辰,张景凤,等.益肾养肝合剂治疗肝肾不足型绝经后骨质疏松症临床观察[J].中草药,2005,36(6)：898—899
[13]光爱珍.六昧地黄丸加虎潜丸治疗绝经后骨质疏松症[J].中国民间疗法,2010, 18(4)：41
[14]阿依加曼·阿不拉,艾合买提·托合尼亚孜.绝经后骨质疏松症治疗133例分析[J].新疆医科大学学报,2006,29(6)：548—549
[15]张银萍,崔英华,康红钰,等.实骨饮对绝经后骨质疏松症患者骨形成、破坏指标的影响及疗效观察[J].新中医,2007, 39(1)：30-31
[16]章林.补肾括血汤治疗绝经后骨质疏松症30例临床观察[J].湖南中医药导报,2004,10(6)：52—53,87
[17]李煜明.补肾活血剂治疗绝经后骨质疏松症60例[J].南京中医药大学学报,2005, 21(1)：56—57
[18]莫传伟.绝经后骨质疏松症中医证候特征及生存质量研究[D].广州中医药大学,2005：1—3
[19]李青南.淫羊藿提取液对去睾丸大鼠代谢的影响[J].中草药,1993, 24(12)：637
[20]熊鹏程,甘学文.补肾健脾活血方对大鼠成骨细胞增殖的影响[J].湖北中医杂志,2006,28(1)：9-10
[21]漆海如,黄永明.中医药对成骨细胞作用的研究进展[J].中医正骨,2006, 18(1)：66—67
[22]臧洪敏,陈君长,刘亦恒,等.补肾活血方对成骨细胞增殖等生物学特性影响的实验研究[J].药材,2005,28(9)：803—805
[23]汤耿民,沈霖,涂意辉,等.补肾活血方对成骨细胞生长因子TGF-β 1mRNA表达的影响[J].中国中医骨伤科杂志,1999, 7(5)：5—7
[24]肖德建.实用骨质疏松学[M].北京：北京科学出版社,2004.276.
[25]崔寿昌.骨质疏松症的预防[J].中国健康教育,2006,22(7)：528-530
[26]郭华平,等.绝经后骨质疏松症发病相关危险因素分析及预防措施探讨[J].中国康复医学杂志,2011,26(5)
[27]周亮,江钟立,林枫,等.青年人和老年人词汇联想反应的研究[J].中国康复医学杂志,2008,23(4)：297—300
[28]徐洁,赵东宝,刘文斌.上海市社区中老年人骨密度相关影响因素分析[J].中国康复医学杂志,2010,25(1)：68—69
[29]郭华平等.绝经后骨质疏松症发病相关危险因素分析及预防措施探讨[J].中国康复医学杂志,2011年,26(5)
[30]Guadalupe-Grau A, Fuentes T, Guerra B, etal. Exercise and bone mass in adults[J]. Sports Medicine,2009,39(6):439—468
[31]de Matos O, Lopesda Silva DJ,Martinez de Oliveira J, et al. Effect of specific exercise training on bone mineral density in women with postmenopausal osteopenia or osteoporosis [J]. Gynecological Endocrinology,2009,25(9):616-620
[32]刘忠厚,主编.骨矿与临床[M].北京：中国科学技术出版社,2006：641
[33]M anolagas SC. Birth and death of bone cells:basic regulatory me chanisms and implications for the pathogenesis and treatment of osteoporosis[J]. Endocrine Reviews,2000,21(2):115-137
[34]M anolagas SC,Kousteni S. Perspective non-reproductive sites of action of reproductive hormones[J]. Endocrinology,2001,142 (6):2200-2204
[35]Kousteni. S, Chen JR, Belli do T, et a.1 Reversal of bone loss in mice by non-genotropic signaling of sex steroids[J].Science,2002,298(5594):843—846
[36]赵荣,陶静.原发性骨质疏松症的病因学研究进展[J].云南中医学院学报,2007,30(2)：67—70
[37]Kallio DM, Garant PR, Minkin CU ltrastructural effects of calciton in on osteoclasts in tissue culture[J]J U ltrastruct Research,1972,39(3).205—216
[38]高建军,周轶,顾淑珠,等.依降钙素对破骨细胞的作用观察[J].中国骨质疏松杂志,2002,8(3)248—252
[39]赵荣,陶静.原发性骨质疏松症的病因学研究进展[J].云南中医学院学报,2007, 30(2)：67—70
[40]邵洵.老年人骨质疏松临床症状及流行病因分析[J].中国健康月刊2010年第29卷第7期
[41]The National Osteoporosis Risk Assessment, NORA
[42]Wu XP, Liao EY, Huang G, et al.A comparison study of the reference curves of bone mineral density at different skeletal sites in native Chinese, Japanese, and American Caucasian women. Calcif Tissue Int,2003,73:122-132
[43]Koh LK, Sedrine WB, TorralbaTP, et al.Asimple tool to identify asianwomen at increased risk of osteoporosis. Osteoporos Int.,2001,12(8):699—705
[44]朱汉民.原发性骨质疏松症防治的进展和趋势.老年医学与保健,2003,9：67—68
[45]Sambrook P, Cooper C. Osteoporosis. Lancet,2006,17:201022018. of osteoporosis. Osteoporos Int.,2001,12(8):699—705
[46]朱继衍,杨蕊敏.老年人骨折与骨密度及骨代谢生化测定探讨.中国老年志,2002,22：190—191
[47]Hernandez MV.Guanabens N, Alvarez L, et al. Immunocytochemical evidence on the effects of glucocorticoids on type I collagen synthesis in human osteoblastic cells. Calcif Tissue Int,2004,74:284-293
[48]Li Y L,Li YY, An Y Q. The effect of monos odium glutamate on the growth and immue function in rat. Journal of Capital University of medical sciences,1997,18(3):210 —221
[49]G arcia2Perez MA, Moreno2Mercer J, Tarin JJ, et al. Similar efficacy of low and standard doses of transdermal estradiol in controlling boneturnover in postmenopausal women. G ynecol Endocrinol,2006,22(4):179—184
[50]Sornay RE, Munoz F, Garnero P, et al. Identification of osteopenic women at high risk of fracture. J Bone Miner Res,2005,20:1813—1819
[51]Wolfe-BM, Huff MW. Effects of continuous low-dosage hor-monal replacement therapy on lipoprotein metabolism in post-menopausal women. Metabolism,1995,44(3):410—417
[52]黄毅,王越.激素替代疗法治疗骨质疏松症的现状和展望[J].医药报,2000,19(2)：177-178
[53]黄德芳,高玉芬,朱明月,等Rallaoxifene对去卵巢大鼠子宫内膜的影响[J].中国骨质疏松杂志,2001,7(3)：241—243
[54]Ott SM. Clinical effects of bisphosphonates in involutional os-teoporosis[J]. JBone Miner Res,1993,8(S2):S597-606
[55]徐春生,叶仁青.氟化物在骨质疏松症治疗中的应用[J].国外医学内分泌学分册,1998,18(2)：78—81
[56]Startoris DJ, Editor. Osteoporosis-diagnosis and treatment [M]. New York:Marcel Dekker,1996,303
[57]Lindsay R. Fluoride and bone:quantity versus quality[J]. NEngl J Med,1990,322 (12):845-846
[58]Riis B, Thomsen AL. Does calcium supplementation prerentp ostmenopausal bone loss? [J]. N Engl J Med,1987,316(4):173-177
[59]Recker R, Kimmwl DB, Hinders, et al. Determinants of en-dogenous fecal calcium in healthy weren[J]. J Bone MinerRes,1994,9(Suppl 1):S154
[60]Brennan MJ. In vitro dissolution of calcium carbonate preparations[J]. Calcif Tissue Int,1991,49 (5):308—312
[61]徐淑云,等.临床药理学.北京人民卫生出版社,2004,7(3)：403-413.
[62]Baltas CS. Balanika AP, Raptou PD, et al. Clinical practice guidelines proposed by the Hellenic Foundation of Osteoporosis for the management of osteoporosis based on DXA results[J]. J Musculoskelet Neuronal Interact,2005,5(4):388-392.
[63]Arimandi BH, Ahekel L, Hollis BW, et al. Dietary soybeanproteinprevents bone loss in an ovariectomized rat model ofosteoporosis[J]. J Nutr,1996,42(6):161—167
[64]Arimandi BH, Birnbaum R, Goyal NV, et al. Bone-sparingeffect of soyprotein in ovarian-homone deficient rats is related to its is oflavonecontent[J]Am J clin Mctr,1998,68(Sup-pl):1364-1368
[65]Somekama Y,Chiguchi M,Zshibashi T, et al Soy intake relat-ed to menopausal symptoms, serum lipids and bone mineral density in postmenopausal Japanese woman[J]Obstet Gynecol,2001,97(1):109—115
[66]赵玉堂,刘凯军,李金花,等.骨矿含量与肾虚、肾主骨关系的研究[J].中国骨质疏松杂志,1996,2(3)：19—22
[67]黄永明,许少健,石宇雄,等.骨松安胶囊治疗绝经后骨质疏松症34例[J],陕西中医2006,27(8)：954-956
[68]姚新苗.益骨汤含药血清对成骨细胞增殖和ALP影响的实验研究[J].浙江中医药大学学报,2007,31(2)：1—2
[69]张拔山,曾龙宏,等.2型糖尿病患者骨代谢生化指标的临床意义[J].放射免疫学杂志,2004,17(4)：251—253
[70]李青南.淫羊藿提取液对去睾丸大鼠代谢的影响[J].中草药,1993, 24(12)：637
[71]安胜军.雌激素、雌激素受体、雌激素受体基因与骨质疏船[J].现代康复.2001,5(2)：7—8
[72]SUDA T, NAKAMURA I, JIMI E, et al. Regulation of osteoclast function[J]. J Bone Miner Res.1997,12:869-879
[73]Herrmann M, Seibol M. The alnlno and carboxyterminal corss-linked telopeptldes of collagen type Ⅰ. NTX-Ⅰ and CTX-Ⅰ:a comparative re-view[J]. Clinical Chimica Aeta, 2008,393:57-75
[74]甘洁民,缪应新,朱汉民.骨代谢生化标志物的分析与临床参考值的设立[J].老年医学与保健,2005,11：165—167
[75]Ross PD, Knowlton W. Rapid bone loss is associated with increased levels of biochemical markers [J]. J Bone Miner Res,1998,13:297—302
[76]Rotteveel J, Schoute E, Delemarre W, et al. Serum procollagen I carboxyterminal pmpepf ide(PICP) levels through puberty:relation to height velocity and serum hormone levels [J]. Acta Pediatrica,1997,86(2):143-147
[77]Jacques PB, Caroline A, Bassam AN, et al. Bone turnover markers in the management of postmenopausal osteoporosis[J]. Clin Biochem,2009,42(10—11): 929-942
[78]Dommguez CC, Sosa HM, Traba ML et al. Biochemical markers of bone formetion in the study of postmenopausal osteoporosis.Osteoporosis Int.1998,27 (2):147—151
[79]Gamero P. Delmas PD. Biochemical markers of turnover. Endocrinol Metab Clin North Am.1998,27(2):303-322
[80]Germero P.Delmas PD Osteoporosis Endoctmal Metab Clin North Am.1997,26(2):913-936
[81]Lursetto G, Bottega F. Nardi A et al. Decrease of bone formation in adult women with fragility fractures Matunatas,1997,28(1):59—67
[82]杨波,舒娜翎,崔党珍,等.健康中老年人768例血浆骨源性ALP测定结果分析[J],中国误诊学杂志,2005,15(5)：2909.